These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6652633)

  • 1. Effect of disulfiram on cyclophosphamide toxicity: a clinical trial.
    Ershler WB; Hacker MP; Newman RA; Stewart JA; Gamelli RL; Krakoff IH
    Cancer Treat Rep; 1983 Dec; 67(12):1145-7. PubMed ID: 6652633
    [No Abstract]   [Full Text] [Related]  

  • 2. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: initial safety and toxicity data.
    Salvatore JR; Harrington J; Kummet T
    Bioelectromagnetics; 2003 Oct; 24(7):524-7. PubMed ID: 12955758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
    Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
    Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
    Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
    Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The leucocyte nadir, a predictor of chemotherapy efficacy?
    Kvinnsland S
    Br J Cancer; 1999 Aug; 80(11):1681. PubMed ID: 10468282
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
    Marschner N; Kreienberg R; Souchon R; Räth U; Eggeling B; Voigtmann R; Ruffert K; Schütte M; Ammon A; Kesztyüs T
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):10-6. PubMed ID: 8153652
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
    Young SD; Whissell M; Noble JC; Cano PO; Lopez PG; Germond CJ
    Clin Cancer Res; 2006 May; 12(10):3092-8. PubMed ID: 16707607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
    Recchia F; De Fillipis S; Piccinini M; Rea S
    Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
    Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
    Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
    Tiersten A; Wo J; Jacobson C; Weitzman A; Horwich T; Hesdorffer C; Savage D; Troxel A
    Breast; 2004 Aug; 13(4):341-6. PubMed ID: 15325671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P; Nolte S; Shahin MS
    Gynecol Oncol; 2002 May; 85(2):278-84. PubMed ID: 11972388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
    Tashiro H; Takahashi I; Yamamura S; Ishikawa T; Yanaga K; Wakasugi K; Matsusaka T; Kume K
    Gan To Kagaku Ryoho; 1999 May; 26(6):775-9. PubMed ID: 10410146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.